Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Junta Sakakibara Clear advanced filters

  • Takada, Gunarathna et al. analyze circulating chromatin fragments in metastatic breast cancer patients treated with abemaciclib. Their findings show that cfDNA reflects drug-induced molecular responses and implicates Polycomb signaling in therapy effectiveness, providing a non-invasive marker of treatment response.

    • Mamoru Takada
    • Sakuntha Gunarathna
    • Motoki Takaku
    ResearchOpen Access
    Communications Medicine
    P: 1-13

  • A total of 1074 patients with a history of ischemic stroke enrolled in The Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study were assigned to intensive blood pressure (BP) control group (blood pressure < 120/80 mmHg) or standard blood pressure control group (blood pressure < 140/90 mmHg) and were followed up for a mean of 3.9 years. Seventy-eight first recurrent strokes occurred, including 70 ischemic stroke and 8 intracerebral hemorrhage. Intensive treatment did not change annual risk of ischemic stroke (1.74% vs. 1.75%, P = 0.999), but markedly reduced risk of hemorrhagic stroke (0.00% vs. 0.39%, P = 0.005). Beneficial effect of intensive BP control were observed for risk of hemorrhagic stroke in the patients with a history of ischemic stroke.

    • Kazuo Kitagawa
    • Hisatomi Arima
    • Seigo Nakada
    Research
    Hypertension Research
    Volume: 45, P: 591-601